Company Overview and News

5
Huntington (HBAN) Up 10.9% YTD: What's Driving the Stock?

2018-09-11 zacks
Of late, the finance sector has been putting up an impressive performance, with some monthly volatility. The United States’ economic health, on which this sector is largely dependent, has been displaying steady improvement with increasing real GDP numbers, declining unemployment rate, improving consumer spending and stabilizing housing market. A stronger-than-expected U.S. payroll data released last week has raised expectations for the Fed interest rate hike in September — the third this year.
HBAN HBANN HBANO HBANP STI CMA STI-A MPC

4
Why Is Huntington Bancshares (HBAN) Up 5.7% Since Last Earnings Report?

2018-08-24 zacks
It has been about a month since the last earnings report for Huntington Bancshares (HBAN - Free Report) . Shares have added about 5.7% in that time frame, outperforming the S&P 500.
HBAN HBANN HBANO HBANP

19
Sinking Or Swimming A Few Ideas - The Idea Guide

2018-08-18 seekingalpha - 2
Today's Idea Guide looks at a few ideas on companies whose futures seem to be pointed in one direction, to see if the market is right or just overreacting.
HBANN HBANO FIT HBANP LUB GOLF MANU HBAN GPRO ZNGA DRYS VALU AAPL DCIX KHC SND

30
3 Big Stock Charts for Friday: Freeport-McMoRan, Royal Caribbean Cruises and Huntington Bancshares

2018-08-03 investorplace - 1
It took some coaxing, but when push came to shove later on the day on Thursday, it was the bulls doing most of the shoving. The S&P 500 ended the day at 2827.22, up 0.49%, led by Apple (NASDAQ:AAPL) and Advanced Micro Devices (NASDAQ:AMD). The technology trade is back “on,” and those two names have been the most reliable leaders of late.
HBAN GPRO HBANN HBANO HBANP AAPL FCX RCL AMD

12
Why Huntington Bancshares (HBAN) is a Top Dividend Stock

2018-07-31 zacks
All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.
HBAN CWH HBANN HBANO HBANP

4
Huntington Bancshares (HBAN) Q2 2018 Results - Earnings Call Transcript

2018-07-25 seekingalpha
Greetings and welcome to the Huntington Bancshares' Second Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded.
HBAN HBANN HBANO HBANP DB MS

6
Huntington (HBAN) Q2 Earnings Beat Estimates, Revenues Rise

2018-07-25 zacks
Huntington Bancshares (HBAN - Free Report) reported second-quarter 2018 earnings per share of 30 cents, beating the Zacks Consensus Estimate by a penny. Also, the figure came in higher than the prior-year quarter adjusted earnings of 26 cents.
HBANN SBNY HBANO HBANP DB WBSFW SBNYW RF HBAN WBS CIT

4
Huntington Bancshares Incorporated 2018 Q2 - Results - Earnings Call Slides

2018-07-25 seekingalpha
The following slide deck was published by Huntington Bancshares Incorporated in conjunction with their 2018 Q2 earnings call.
HBAN HBANN HBANO HBANP

4
Huntington (HBAN) Q2 Earnings Beat Estimates, Revenues Rise

2018-07-25 zacks
Have you been eager to see how Huntington Bancshares Incorporated (HBAN - Free Report) performed in Q2 in comparison with the market expectations? Let’s quickly scan through the key facts from this Ohio-based bank’s earnings release this morning:
HBAN HBANN HBANO HBANP MS

5
Will Rising Rates Support Huntington (HBAN) Q2 Earnings?

2018-07-23 zacks
Huntington Bancshares (HBAN - Free Report) is scheduled to report second-quarter 2018 results on Jul 25, before the opening bell. The company’s results are projected to reflect year-over-year growth in revenues and earnings. In the last reported quarter, the company’s earnings were in line with the Zacks Consensus Estimate. Higher revenues, continued growth in both loan and deposit balances, and lower provisions were among the positives.
HBAN HBANN HBANO HBANP LMHA SIVB CFR LMHB LM

63
Bank Stock Roundup: Q2 Earnings Season Unfolds, JPMorgan, BofA & Citi Top Estimates

2018-07-20 zacks
Most banks that reported second-quarter 2018 results this week managed to record bottom-line improvement on the back of rising rates, lower provisions and improved trading activities. This also led to positive price movement for most bank stocks over the last five trading days. In addition to the benefits from higher interest rates, banks’ results mirrored a marginal upswing in loans. Moreover, the results display eased margin pressure.
WFCNP HBANN ZIONW HBANO HBANP FITBI PB BAC USB ZBK ZION BKU WFC BAC C HBAN FITB CFR ZIONZ

5
Associated Banc-Corp (ASB) Beats on Q2 Earnings, Costs Rise

2018-07-20 zacks
Associated Banc-Corp’s (ASB - Free Report) second-quarter 2018 earnings of 50 cents per share surpassed the Zacks Consensus Estimate of 48 cents. Also, the figure compares favorably with the prior-year quarter’s earnings of 36 cents. The reported quarter’s earnings included acquisition-related costs in connection with the Bank Mutual deal. Excluding the acquisition-related costs, adjusted earnings for the quarter were 53 cents per share.
HBANN HBANO HBANP BKMU ASB-D ASB-C PB HBAN BKU ASB

6
Huntington Bancshares: A Reasonable Amount Of Risk For A 5.87% Yield

2018-07-17 seekingalpha - 2
While the bank is profitable, loan earnings have come under pressure with the flattening of the yield curve.
HBAN HBANN HBANO HBANP

25
The Zacks Analyst Blog Highlights: M&T Bank, Customers Bancorp, Metropolitan Bank Holding and Triumph Bancorp

2018-07-11 zacks
Chicago, IL – July 11, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include M&T Bank Corp. (MTB - Free Report) , Customers Bancorp, Inc. (CUBI - Free Report) , Metropolitan Bank Holding Corp. (MCB - Free Report) and Triumph Bancorp, Inc.
LPLA WFCNP MOV HBANN HBANO HBANP IBKR CUBS RF MOVAA SFIX LSTR HOLI FITBI TBK STI-A MCB WFC SCHN HBAN STI CUBI FITB PETS URBN

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

16h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

16h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

18h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 446150904